EGFR and non-small cell lung carcinoma: Based on the above researchs, we propose for patients with Lung-molGPA 2.5–4 that upfront WBRT followed by EGFR-TKI therapy would be a better treatment strategy in the treatment for EGFR-mutant NSCLC with symptomatic multiple BMs.